List of Solosec drug patents
Solosec is owned by Lupin.
Solosec contains Secnidazole.
Solosec has a total of 8 drug patents out of which 0 drug patents have expired.
Solosec was authorised for market use on 15 September, 2017.
Solosec is available in granule;oral dosage forms.
Solosec can be used as treatment of bacterial vaginosis in adult women; treatment of trichomoniasis in adults; treatment of bacterial vaginosis in female patients 12 years of age and older; treatment of trichomoniasis in patients 12 years of age and older, treatment of trichomoniasis in patients 12 years of age and older; treatment of bacterial vaginosis in female patients 12 years of age and older; treatment of trichomoniasis in adults; treatment of bacterial vaginosis in adult women, treatment of bacterial vaginosis in adult women; treatment of bacterial vaginosis in female patients 12 years of age and older, treatment of bacterial vaginosis in female patients 12 years of age and older; treatment of trichomoniasis in patients 12 years of age and older; treatment of trichomoniasis in adults; treatment of bacterial vaginosis in adult women, treatment of bacterial vaginosis in female patients 12 years of age and older; treatment of bacterial vaginosis in adult women.
Drug patent challenges can be filed against Solosec from September, 2026.
The generics of Solosec are possible to be released after 04 September, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335390 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
| US11000507 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
| US11020377 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
| US11000508 | LUPIN | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(12 years from now) | |
| US10682338 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
| US10849884 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
| US10857133 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
| US11324721 | LUPIN | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 15, 2022 |
| New Indication (I) | Jun 30, 2024 |
| New Patient Population (NPP) | Jan 26, 2025 |
| Generating Antibiotic Incentives Now (GAIN) | Sep 15, 2027 |
Drugs and Companies using SECNIDAZOLE ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 15 September, 2017
Treatment: Treatment of bacterial vaginosis in adult women; Treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of trichomoniasis in patients 12 years of age and older; Treatment of trichomoniasis in adults
Dosage: GRANULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic